Daan Gene disclosed its semi-annual performance report on 28 July. In the first half of the year, the company achieved a total operating income of 6.676 billion CNY, a year-on-year increase of 91.68%; net profit attributable to the parent was 3.557 billion CNY, a year-on-year increase of 122.59%; basic earnings per share was 2.5343 CNY.

During the reporting period, the market continued to demand COVID-19 nucleic acid detection kits, nucleic acid detection instruments, and related consumables, which had a positive impact on the company's performance.